Examining the Impact of Using Two Dialysers in Parallel on Dialysis Adequacy in Hemodialysis Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01539252|
Recruitment Status : Completed
First Posted : February 27, 2012
Last Update Posted : December 8, 2016
|Condition or disease||Intervention/treatment||Phase|
|End Stage Renal Disease||Procedure: Single dialyzer Procedure: Two dialyzers||Not Applicable|
Higher levels of serum phosphate are independently associated with an increased risk of death in hemodialysis patients. Therefore, there has been considerable interest in controlling serum phosphate while minimizing oral calcium load. While most attention has focused on the use of non-calcium containing phosphate binders such as sevelamer and lanthanum, modifying conventional dialysis regimens to improve phosphate clearance is an alternative approach that remains relatively unstudied. A secondary analysis of a previous randomized cross-over study from our group found that the use of two dialysers in parallel resulted in a reduction in pre-dialysis serum phosphate levels. As this study was small, and the mechanisms resulting in the reduction in phosphate levels were unclear, further study is warranted. The investigators will conduct a randomized cross-over study comparing the impact of dialyzing using two dialysers in parallel with a single dialyser in hyperphosphatemic hemodialysis patients.
There will be a total of 34 participants from Alberta,Canada participating in this study. The length of study participation is 10 weeks.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||33 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||Examining the Impact of Using Two Dialysers in Parallel on Dialysis Adequacy in Hemodialysis Patients|
|Study Start Date :||January 2013|
|Actual Primary Completion Date :||November 2014|
|Actual Study Completion Date :||December 2014|
Active Comparator: Single dialyzer
Procedure: Single dialyzer
Hemodialysis treatment using a single Baxter dialyzer - considered standard hemodialysis treatment.
Experimental: Double dialyzer
Two dialyzers in parallel
Procedure: Two dialyzers
Hemodialysis treatment using a two Baxter dialyzers in parallel.
- Dialysate clearance of phosphate [ Time Frame: 3 weeks ]Dialysate phosphate clearance levels in double dialyzer periods compared to single dialyzer periods.
- Serum phosphate [ Time Frame: 3 weeks ]Serum phosphate levels in the double dialyzer periods compared to the single dialyzer periods.
- Dialysate removal of phosphate [ Time Frame: 3 weeks ]Dialysate removal levels of phosphate in the double dialyzer periods compared to the single dialyzer periods.
- Proportion of participants with serious adverse events [ Time Frame: 30 days following last day of intervention ]The proportion of participants during the double dialyzer period compared to the single dialyzer period experiencing serious adverse events resulting in death, life threatening illness, hospitalization or prolongation of existing hospitalization, or persistent or significant disability.
- Proportion of participants with adverse events [ Time Frame: 30 days following last day of intervention ]The proportion of participants with adverse events (and by each type of adverse event) during the double dialyzer intervention compared to single dialyzer intervention.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01539252
|University of Calgary|
|Calgary, Alberta, Canada, T2N 2T9|
|University of Alberta|
|Edmonton, Alberta, Canada, T6G 2V2|
|Principal Investigator:||Marcello Tonelli, MD||University of Alberta|
|Principal Investigator:||Braden Manns, MD||University of Calgary|